2026 Medical Overview
Understanding Spinal Cord Injury: Why Recovery Is Limited
Spinal cord injury (SCI) remains one of the most challenging conditions in medicine because the central nervous system has very limited ability to repair itself. Unlike skin or muscle, the spinal cord lacks effective regenerative capacity once neural tissue is damaged.
Importantly, injury does not end at the moment of trauma. Beyond the initial mechanical damage (primary injury), a secondary phase follows—driven by inflammation, immune activity, and biochemical changes—that can further damage surrounding neurons over time. This ongoing process often determines long-term outcomes.
As a result, current treatment focuses on stabilizing the spine and optimizing recovery through rehabilitation. However, these approaches do not directly restore damaged neural tissue, which is why regenerative strategies such as stem cell therapy are being increasingly explored.
Why UC-MSCs Are Being Studied in Spinal Cord Injury
Umbilical cord–derived mesenchymal stem cells (UC-MSCs) have gained attention not because they replace damaged spinal cord tissue, but because they influence the biological environment in which recovery occurs.
Rather than acting as building blocks for new neurons, UC-MSCs function mainly through signaling. They release bioactive molecules—such as cytokines, growth factors, and extracellular vesicles—that interact with surrounding cells. This process, known as paracrine signaling, plays a central role in how they support recovery.
In spinal cord injury, where inflammation and immune dysregulation drive ongoing damage, this signaling effect becomes particularly important.
Mechanism of Action: Supporting the Neural Environment
The therapeutic rationale for UC-MSCs in spinal cord injury is based on their ability to modulate the injury environment rather than rebuild the spinal cord itself.
Following injury, excessive inflammation can worsen neuronal damage and inhibit repair. UC-MSCs help regulate this response by reducing pro-inflammatory signaling and promoting a more balanced immune environment, which may limit secondary damage and preserve remaining neural pathways.
They also release neurotrophic factors that support neuron survival and may encourage repair processes. While this does not result in full regeneration, it can contribute to functional improvements—such as better movement or sensation—particularly in patients with partial neural connectivity.
What Global Clinical Evidence Shows
Over the past decade, spinal cord injury has become an active focus in regenerative medicine, with clinical trials evaluating mesenchymal stem cells (MSCs), including UC-MSCs.
Studies generally report that MSC therapy is well-tolerated under controlled medical conditions, with relatively low and manageable adverse events.
Some patients show improvements in neurological function—such as motor strength, sensation, or independence—often measured using tools like the ASIA scale, particularly in incomplete injuries. However, outcomes remain variable and depend on factors such as injury severity, timing of treatment, and rehabilitation.
The Critical Role of Injury Severity
Among all factors influencing outcomes, the severity and type of spinal cord injury remain the most important. Patients with incomplete injuries—where some degree of motor or sensory function is preserved—tend to have a higher potential for improvement. In these cases, UC-MSC therapy may help support existing neural pathways and enhance recovery processes.
In contrast, patients with complete spinal cord injury, where there is total loss of function below the level of injury, face a much more limited prognosis. While stem cell therapy may still contribute to improvements in aspects such as inflammation or secondary complications, the likelihood of significant functional recovery is considerably lower.
This distinction is essential for setting realistic expectations and is a key part of responsible medical decision-making.
Treatment Approaches and Delivery Methods
Globally, UC-MSC therapy for spinal cord injury is delivered through several routes, each with different theoretical advantages.
Intravenous (IV) administration is commonly used for its systemic effects, particularly in reducing inflammation and modulating immune activity throughout the body. Intrathecal delivery, which involves injection into the cerebrospinal fluid, is designed to provide more direct interaction with the central nervous system. In some research settings, local injections at the injury site have also been explored, although these approaches are less commonly used in routine clinical practice.
The choice of delivery method depends on multiple factors, including the patient’s condition, the clinical protocol, and safety considerations.
Timeline of Recovery and Expected Outcomes
Stem cell therapy does not produce immediate results. In the early phase after treatment, changes occur primarily at the cellular level—particularly in inflammation and signaling pathways—which are not immediately visible but may support later functional improvement.
Clinical observations suggest that early changes may appear within one to three months, with more noticeable improvements developing over three to six months. During this period, rehabilitation remains essential, as outcomes depend on the nervous system’s ability to adapt and reorganize.
Where UC-MSC Therapy Fits in Clinical Practice
From a clinical perspective, UC-MSC therapy is best understood as an adjunctive treatment rather than a replacement for standard care.
It does not substitute for surgery when structural stabilization is required, nor does it replace rehabilitation. Instead, it may complement these approaches by improving the biological environment that supports recovery.
For this reason, UC-MSC therapy is most appropriately used within a structured treatment plan that includes medical evaluation, imaging, and ongoing rehabilitation.
FAQs
- Can stem cell therapy cure spinal cord injury?
No. Stem cell therapy is not a cure and does not regenerate a fully damaged spinal cord. It is used as a supportive treatment to enhance recovery conditions. - Who is most likely to benefit?
Patients with incomplete spinal cord injury and preserved neurological function generally have higher potential for improvement. - How long does it take to see results?
Improvements, if they occur, are typically observed over several months rather than immediately after treatment. - Is this treatment widely approved?
Stem cell therapy for spinal cord injury is still considered investigational in many regions, although it is widely studied and used under regulated medical frameworks.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation:
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
www.ednawellness.com
References
- Cheng H, Liu X, Hua R, Dai G, Wang X, Gao J, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. Journal of Translational Medicine. 2014;12:253. https://link.springer.com/article/10.1186/s12967-014-0253-7
- Yang Y, Pang M, Du C, Liu Z, Chen Z, Wang N, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy. 2021. https://www.isct-cytotherapy.org/article/S1465-3249(20)30903-8/fulltext
- Awidi A, Al Shudifat A, El Adwan N, Alqudah M, Jamali F, Nazer F, et al. Safety and potential efficacy of expanded mesenchymal stromal cells of bone marrow and umbilical cord origins in patients with chronic spinal cord injuries: a phase I/II study. Cytotherapy. 2024;26(8):825-831. https://www.sciencedirect.com/science/article/pii/S146532492400570X
- Yang Y, Pang M, Chen YY, Zhang LM, Liu H, Tan J, Liu B, Rong LM. Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial. Neural Regeneration Research. 2020;15(8):1532-1538. https://pmc.ncbi.nlm.nih.gov/articles/PMC7059580/
- de Araújo LT, Macêdo CT, Damasceno PKF, das Neves ÍGC, de Lima CS, Santos GC, et al. Clinical Trials Using Mesenchymal Stem Cells for Spinal Cord Injury: Challenges in Generating Evidence. Cells. 2022;11(6):1019. https://www.mdpi.com/2073-4409/11/6/1019
- Xia Y, Zhu J, Yang R, Wang H, Li Y, Fu C. Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges. Frontiers in Immunology. 2023;14:1141601. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1141601/full